Announced details
Treatment of adult patients with insomnia
Partnership. The Company supplies the products, while Holling handles the application and approval process, distribution and sales.
Taiwan's largest pharmaceutical distribution and sales company, headquartered in Taipei, with approximately 50 years of operating history. It provides pharmaceutical registration, market access, product promotion, warehouse management and logistics services, and has experience and expertise in the central nervous system field.
Taipei, Taiwan (Holling's headquarters)
Milestone amounts are undisclosed. The Company is entitled to receive initial sales-related milestone payments, royalties on net sales and revenue from product supply.
The impact on the Company's consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026.
The company does not address Offering price.
Taiwan's National Health Research Institutes (number and percentage of Taiwanese adults with insomnia and other sleep disorders in 2021)
| Item | Details |
|---|---|
| Names of Products / Services Covered | QUVIVIQ® (daridorexant; Taiwan product name: 科唯可®) 25 mg, QUVIVIQ® (daridorexant; Taiwan product name: 科唯可®) 50 mg |
| Counterparty | Holling Bio-Pharma Corp. (Holling) |
| Counterparty overview | Taiwan's largest pharmaceutical distribution and sales company, headquartered in Taipei, with approximately 50 years of operating history. It provides pharmaceutical registration, market access, product promotion, warehouse management and logistics services, and has experience and expertise in the central nervous system field. |
| Relationship with the Company | Partnership. The Company supplies the products, while Holling handles the application and approval process, distribution and sales. |
| Contract Value | Milestone amounts are undisclosed. The Company is entitled to receive initial sales-related milestone payments, royalties on net sales and revenue from product supply. |
| Launch date | Scheduled for launch in Taiwan during 2026 |
| Applicable area | Treatment of adult patients with insomnia |
| Location | Taipei, Taiwan (Holling's headquarters) |
| Impact on Business Performance | The impact on the Company's consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026. |
| Source | Taiwan's National Health Research Institutes (number and percentage of Taiwanese adults with insomnia and other sleep disorders in 2021) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company used materials from its Japanese marketing application and applied for the Taiwan Food and Drug Administration's (TFDA) Streamlined Review Designation.